Posology
The
dosage should be determined by the physician, according to the
requirement of the patient.
Humalog
may be given shortly before meals. When necessary Humalog can be
given soon after meals.
Humalog
takes effect rapidly and has a shorter duration of activity (2 to
5 hours) given subcutaneously as compared with soluble insulin.
This rapid onset of activity allows a Humalog injection to be given
very close to mealtime. The time course of action of any insulin may
vary considerably in different individuals or at different times in
the same individual. The faster onset of action compared to soluble
human insulin is maintained regardless of injection site. The
duration of action of Humalog is dependent on dose, site of
injection, blood supply, temperature, and physical activity.
Humalog
can be used in conjunction with a longer-acting insulin or oral
sulphonylurea medicinal products, on the advice of a physician.
Humalog
KwikPens
Humalog
KwikPen is available in two strengths.The Humalog 200 units/ml
KwikPen delivers 1–60 units in steps of 1 unit in a single
injection. The
number of insulin units is shown in the dose window of the pen
regardless of strength
and no
dose
conversion should be done when transferring a patient to a new
strength or to a pen with a different dose step.
Humalog
200 units/ml KwikPen should be reserved for the treatment of
patients with diabetes requiring daily doses of more than 20 units of
rapid-acting insulin. The insulin lispro solution containing
200 units/ml should not be withdrawn from the pre-filled pen
(the KwikPen) or mixed with any other insulin.
Special
populations
Renal
impairment
Insulin
requirements may be reduced in the presence of renal impairment.
Hepatic
impairment
Insulin
requirements may be reduced in patients with hepatic impairment due
to reduced capacity for gluconeogenesis and reduced insulin
breakdown; however, in patients with chronic hepatic impairment, an
increase in insulin resistance may lead to increased insulin
requirements.
Method
of administration
Humalog
solution for injection should be given subcutaneously.
Subcutaneous
administration should be in the upper arms, thighs, buttocks, or
abdomen. Use of injection sites should be rotated so that the same
site is not used more than approximately once a month,
in
order to reduce the risk of lipodystrophy and cutaneous amyloidosis.
When
administered subcutaneously care should be taken when injecting
Humalog to ensure that a blood vessel has not been entered. After
injection, the site of injection should not be massaged. Patients
must be educated to use the proper injection techniques.
Humalog
200 units/ml KwikPen solution for injection should not be used
in an insulin infusion pump.
Humalog
200 units/ml KwikPen solution for injection should not be used
intravenously.
Reference
Humalog
200 Units/ml [Summary of Product Characteristics]. Utrecht, The
Netherlands: Eli Lilly Nederland B.V.